Stock Market

It’s official. One of the hot IPOs of 2023 has priced its initial public offering.  On Wednesday, Sept. 13, Arm Holdings (NASDAQ:ARM) got the last laugh. The U.K.-based chip designer originally sold itself to Nvidia (NASDAQ:NVDA) in 2022 for $40 billion, but regulators nixed the deal. Its shares were priced at $52 for a market
0 Comments
For the long term, I like the growth prospects of electric vehicle (EV) manufacturer Tesla (NASDAQ:TSLA). However, financial traders need to time their entry points carefully with TSLA stock. That’s a challenging task when Tesla’s chief executive is unpredictable. Some questions remain unanswered in 2023, it seems. Is Tesla’s strategy to lower its EV prices, or
0 Comments
Microsoft (NASDAQ:MSFT) is a member of the “Magnificent Seven” group of tech firms. However, don’t assume that MSFT stock will deliver magnificent returns like it did in 2023’s first half. Sure, Microsoft’s investors will get exposure to the artificial intelligence market. Yet, current and prospective shareholders should be aware of a significant competitor that Microsoft will
0 Comments
Plenty have thrown in the towel with positions in Lucid Group (NASDAQ:LCID), but many analysts and investors remain optimistic about the future prospects of LCID stock. While others have headed for the exits, they’ve held on, continuing to argue the consistently-questionable bull case for the struggling electric vehicle maker’s shares. In fact, just recently, the
0 Comments
Recent industry and macro factors caused Nvidia (NASDAQ:NVDA) stock to dip, sparking concerns about its 2023 rally. Despite a slight decline, don’t dismiss the ongoing generative AI mega trend driving its powerful performance.  That said, investors should recognize the limits of Nvidia’s growth potential despite the market’s enthusiasm for AI. While NVDA benefits from AI
0 Comments
The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist (VC) companies increased investments from 2,200 in 2016 to 3,100 in 2021 in biotechnology (biotech) startups. These startups have advanced medicine overall, improving cell therapy, tissue regeneration, genetic medicine, and more. With increasing innovation, we see
0 Comments